Eli Lilly Claims Experimental Drug Protects Covid-19 Patients


A so-called monoclonal antibody lowered levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts. (Ny Times Science) More More

Similar stories

Covid-19 Live Updates: Record Week for U.S. Coronavirus Cases - The New York Times

Covid-19 Live Updates: Record Week for U.S. Coronavirus Cases  The New York Times

Posted on 27 October 2020 | 12:17 pm | Google News

Coronavirus update: U.S. case tally tops 8.7 million and marks seven-day record, with more than 20 states seeing most new cases since start of the outbreak - MarketWatch

Coronavirus update: U.S. case tally tops 8.7 million and marks seven-day record, with more than 20 states seeing most new cases since start of the outbreak  MarketWatch

Posted on 27 October 2020 | 11:34 am | Google News

Covid-19: Eli Lilly Says Its Antibody Treatment Does Not Work on Hospitalized Virus Patients - The New York Times

Covid-19: Eli Lilly Says Its Antibody Treatment Does Not Work on Hospitalized Virus Patients  The New York Times

Posted on 27 October 2020 | 9:31 am | Google News

Vaccine updates: Japan's cabinet approves plan for free COVID-19 shots - Gulf News

Vaccine updates: Japan's cabinet approves plan for free COVID-19 shots  Gulf News

Posted on 27 October 2020 | 8:59 am | Google News

COVID-19 tracker: NIH halts combo trial of Gilead's Veklury, Lilly's antibody; Early COVID drugs won't be a 'home run' - FiercePharma

COVID-19 tracker: NIH halts combo trial of Gilead's Veklury, Lilly's antibody; Early COVID drugs won't be a 'home run'  FiercePharma

Posted on 27 October 2020 | 8:30 am | Google News

Why Eli Lilly's September Earnings Disappointed Wall Street - Barron's

Why Eli Lilly's September Earnings Disappointed Wall Street  Barron's

Posted on 27 October 2020 | 8:16 am | Google News

Copyright © 2020 LastMinuteStuff.com | Contact info